Erlotinib is a medication used to treat non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR). It works by blocking the activity of EGFR, which can slow down or stop the growth of cancer cells.

Ramucirumab is a medication that targets and blocks a protein called VEGFR-2, which is involved in the formation of blood vessels that supply nutrients to tumors. By blocking this protein, ramucirumab can help to slow the growth of cancer by cutting off its blood supply.

Gefitinib is another medication used to treat non-small cell lung cancer with EGFR mutations. Similar to erlotinib, it works by inhibiting the activity of EGFR, thereby slowing the growth and spread of cancer cells.

Osimertinib is a medication used for treating non-small cell lung cancer that has specific mutations, including the T790M mutation. It works by targeting and inhibiting the mutated forms of EGFR, helping to control the growth of cancer cells that have become resistant to other treatments.

Metastatic Non-Small Cell Lung Cancer – This is a type of lung cancer that begins in the cells lining the lungs and has spread to other parts of the body. It is characterized by the uncontrolled growth of abnormal cells in the lung tissue, which can form tumors. As the disease progresses, these cancerous cells can invade nearby tissues and organs, and eventually spread to distant parts of the body through the bloodstream or lymphatic system. The progression of the disease can lead to symptoms such as persistent cough, chest pain, and difficulty breathing. The presence of specific genetic mutations, such as those in the epidermal growth factor receptor (EGFR), can influence the behavior and progression of the cancer.